Immunotherapies like the adoptive transfer of gene-engineered T cells and immune
checkpoint inhibitors are novel therapeutic modalities for advanced cancers. However, some …

Adoptive cell therapy using chimeric antigen receptor (CAR) technology is one of the most
advanced engineering platforms for cancer immunotherapy. CAR-T cells have shown …

Summary Interleukin-12 (IL-12) gene transfer enhances the therapeutic potency of adoptive
T cell therapies. We previously reported that transient engineering of tumor-specific CD8 T …

Chimeric antigen receptor (CAR)-expressing macrophages (CAR-M) have a great potential
to improve cancer therapy, as shown from several recent preclinical studies. However …

Background: Hepatocellular carcinoma (HCC) is a highly aggressive malignant disease,
and numerous studies have demonstrated that an inflammatory environment can induce …

Simple Summary To date, different therapeutic strategies, including immunotherapies, have
been shown to prolong survival in breast cancer patients, representing one of the most …

Chimeric antigen receptor T (CAR-T) cell therapy has faced a series of challenges and has
shown very little efficacy in solid tumors to date. Although genetically engineered …

As one of the deadliest cancers of the gastrointestinal tract, there has been limited
improvement in long-term survival rates for gastric cancer (GC) in recent decades. The poor …

Background Macrophages have recently become attractive therapeutics in cancer
immunotherapy. The potential of macrophages to infiltrate and influence solid malignancies …

CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of
immunotherapy against hematological cancers. This report is focused on CAR-T cells …